From parent advocate to nonprofit chief science officer, to biotherapeutic company cofounder — A personal journey through drug development for Angelman syndrome
On May 29, 2020, Allyson Berent will discuss the journey that led her to becoming chief science officer of the largest research funding foundation for Angelman syndrome in the world (Foundation for Angelman Syndrome Therapeutics [FAST]), and the cofounder and chief operating officer of GeneTx Biotherapeutics — a biotech company solely focused on developing an antisense oligonucleotide for the treatment of Angelman syndrome — after her daughter was diagnosed with Angelman syndrome at 5.5 months old.
Group Leader, Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard
On 27 January 2016, Gordon Fishell described his investigations of the developmental and genetic origins of interneuron development.
On 11 November 2015, David S. Mandell talked about why autism interventions rarely are implemented in community practice and why they fail to achieve the same outcomes as those observed in clinical trials.
Investigator, Howard Hughes Medical Institute
On 28 October 2015, Catherine Dulac discussed the cellular and molecular architecture of neural circuits underlying instinctive social behaviors in mice.
Join the SFARI science team and leaders in the autism research community for an informal evening of food, drink, conversation and mingling on 19 October 2015 in Chicago.
On 30 September 2015, Takao Hensch discussed the biological bases of critical periods in brain development.
On 25 March 2015, Maureen Durkin discussed trends in the prevalence of autism and explored some of the reasons underlying the recent rise in autism cases.